Document is current
Any future updates will be listed below
-
Authors
Mohammed, Aisha M.
Olwal, Charles Ochieng’
Fossati, Andrea
Nyakoe, Nancy K.
Fabius, Jacqueline M.
Gordon, Martin
Polacco, Benjamin J.
Swaney, Danielle L.
Awandare, Gordon A.
Krogan, Nevan J.
Bouhaddou, Mehdi
Bediako, Yaw
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01AI152161, R01AI152161, R01AI152161, K99AI163868)
WACCBIP-World Bank ACE Masters/PhD fellowship (WACCBIP+NCDs: Awandare, WACCBIP+NCDs: Awandare)
- License Information
-
More Information
Article History
Received: 23 February 2024
Accepted: 13 January 2025
First Online: 3 February 2025
Declarations
:
: The study protocol was reviewed and approved by Noguchi Memorial Institute for Medical Research Institutional Review Board (NMIMR) (Approval number: NMIMR-IRB CPN 008/17–18). Permission to collect samples from the health facilities was granted by the respective hospital managements. All parents or legal guardians of the participants provided written consent prior to recruitment.
: Not applicable.
: The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche, and Rezo Therapeutics. Nevan Krogan has a financially compensated consulting agreement with Maze Therapeutics. He is the President and is on the Board of Directors of Rezo Therapeutics, and he is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, GEn1E Lifesciences, and Interline Therapeutics.
